Chugai Pharmaceutical Co., Ltd. (CHGCY)

OTCMKTS: CHGCY · Delayed Price · USD
16.04
+0.04 (0.25%)
May 20, 2024, 12:22 PM EDT - Market open
Market Cap 52.78B
Revenue (ttm) 6.64B
Net Income (ttm) 2.09B
Shares Out 3.29B
EPS (ttm) 1.27
PE Ratio 25.00
Forward PE 24.45
Dividend n/a
Ex-Dividend Date n/a
Volume 29,446
Open 15.62
Previous Close 16.00
Day's Range n/a
52-Week Range 12.88 - 22.61
Beta 0.51
Analysts n/a
Price Target n/a
Earnings Date n/a

About CHGCY

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu,... [Read more]

Sector Healthcare
Founded 1925
Employees 7,604
Stock Exchange OTCMKTS
Ticker Symbol CHGCY
Full Company Profile

Financial Performance

In 2023, CHGCY's revenue was 1.11 trillion, a decrease of -11.79% compared to the previous year's 1.26 trillion. Earnings were 325.47 billion, a decrease of -13.08%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.